Trial Profile
A Phase 0 Trial of HB-201 for Subjects With Transoral Resectable Human Papillomavirus 16 Positive (HPV 16+) Oropharynx Cancer or With Locally Advanced Cervical Cancer Treated With Chemotherapy and Radiation
Status:
Discontinued
Phase of Trial:
Phase 0
Latest Information Update: 29 Dec 2023
Price :
$35
*
At a glance
- Drugs HB 201 (Primary)
- Indications Adenocarcinoma; Cervical cancer; Head and neck cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Proof of concept; Therapeutic Use
- Sponsors Hookipa Pharma
- 20 Dec 2023 Status changed from recruiting to discontinued.
- 29 Jun 2023 Planned End Date changed from 1 Aug 2023 to 1 Jun 2025.
- 29 Jun 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Jun 2025.